Haiyan Fu, Ph.D.

Haiyan Fu, PhD, is a principal investigator in the Center for Gene Therapy at the Research Institute at Nationwide Children’s Hospital. Dr. Fu’s NIH and privately funded research program focuses on gene therapy, mechanisms of neuropathology and biomarker development targeting MPS III/lysosomal storage diseases and neurodegenerative diseases.

Languages Spoken:

• English

Research Center:

• Center for Gene Therapy

Areas of Interest:

• The major focus of my research group is to develop efficient approaches for gene delivery to the central nervous system (CNS), using recombinant adeno-associated virus vectors, to treat the neurological disease of Mucopolysaccharidosis (MPS) IIIB in patients. We also interested in mechanisms of post-transcriptional and post-translational modification of a-N-acetylglucosaminidase (the enzyme missing in MPS IIIB patients), which are critical for the function of the enzyme and the effectiveness of gene therapy. Another aspect of our research is understanding how the lysosomal storage of heparan sulfate, which is the primary consequence of the enzyme deficiency, activates different aspects of innate and adaptive immunity, and how the CNS immune response, especially the CNS T-cell autoimmunity, contributes to neuropathology and MPS IIIB disease progression. We are also implementing immune intervention strategies for therapeutic development for lysosomal storage diseases.

Medical School

• Loude College, Shandong Med. University
  Date Completed: 06/30/1979

Graduate School

• Chinese Acad. Prevent. Med.
  Date Completed: 06/30/1988

Post Doctoral

• Institute for Animal Health
  Date Completed: 06/30/1995

2004–present

• Assistant Professor, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University, Columbus, Ohio

2000–2004

• Research Assistant Professor, Division of Genetics and Metabolism, Department of Pediatrics, University of North Carolina at Chapel Hill, North Carolina

1998–2000

• Postdoctoral Research Associate in Microbiology and Gene Therapy, Division of Genetics and Metabolism, Department of Pediatrics, University of North Carolina at Chapel Hill, North Carolina

1996–1998

• Postdoctoral Research Associate in Molecular Biology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina

1991–1992

• Visiting Scholar in Microbiology, University of Surrey, UK

1988–1991

• Research Associate in Microbiology, Institute of Microbiology and Epidemiology, Chinese Academy of Preventive Medicine, Beijing, PR China

1979–1985

• Resident and Instructor in Dept. Infectious Diseases and Epidemiology, Loude College, Shandong Medical University, Shandong, PR China

• D.M. McCarty, J. DiRosario, K. Gulaid, J. Muenzer, H. Fu. 2009. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.  Gene Therapy. Vol. 16, no. 11. (November): 1340-1352.
• J. DiRosario, E. Divers, C. Wang, A. Charrier, P. Jukkola, J. Etter, H. Auer, V. Best, D.L. Newsom, D.M. McCarty, H. Fu. 2009. Innate and adaptive immune activation in the brain of MPS IIIB mouse model.  J Neurosci Res..
• H. Fu, L. Kang, J.S. Jennings, S.S. Moy, A. Perez, J. DiRosario, D.M. McCarty, J. Muenzer. 2007. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult Mucopolysaccharidosis IIIB mice.  Gene Therapy. Vol. 14, no. January: 1065-1077.
• D.M. McCarty, H. Fu, P.E. Monahan, C.E. Tolson, P. Naik, R.J. Samulski 10(26):2112-8. 2003. Adeno-associated Virus Terminal Repeat (TR) Mutant Generates Self-complementary Vectors to Overcome Rate-Limiting Step to Transduction In Vivo.  Gene Therapy. Vol. 10, no. January: 2112-2118.
• H. Fu, J. Muenzer, R.J. Samulski, G. Breese, J. Sifford, X. Zeng, D.M. McCarty. 2003. Self-Complementary Adeno-Associated Virus Serotype 2 Vector: Global Distribution and Broad Dispersion of AAV-Mediated Transgene Expression in Mouse Brain.  Mol. Therapy. Vol. 8, no. January: 911-917.
• H. Fu, R.J. Samulski, T.J. McCown, J. Picornell, D. Fletcher, J. Muenzer. 2002. Neurological correction of lysosomal storage in mucopolysaccharidosis IIIB knock-out mouse model by adeno-associated virus-mediated gene delivery.  Mol. Ther. Vol. 5, no. January: 42-49.
• H. Fu, C.J. Leake, P.P. Mertens, P.S. Mellor. 1999. The barriers to bluetongue virus infection, dissemination and transmission in the vector, Culicoides variipennis (Diptera:Ceratopogonidae).  Arch. Virol. Vol. 144, no. January: 747-761.
• Z.T. Kelleher, H. Fu, E. Livanos, B. Wendelburg, S. Gulino, J.M. Vos. 1998. First-generation of mouse artificial episomal chromosomes for shuttling 100 kb of self-replicating human DNA.  Nature Biotechnology. Vol. 16, no. January: 762-768.
• L.A. Martin, A.J. Meyer, R.S. O’Hara, H. Fu, P.S. Mellor, N.J. Knowles, P.P. Mertens. 1998. Phylogenetic analysis of African horse sickness virus segment 10: sequence variation, virulence characteristics and cell exit.  Arch. Virol-Supplementum. Vol. 14, no. January: 281-293.
• P.P. Mertens, J.N. Burrough, A. Walton, M.P. Wellby, H. Fu, R.S. O'Hara, S.M. Brookes, P.S. Mellor. 1996. Enhanced infectivity of modified bluetongue virus particles for two insect cell lines and for two Culicoides vector species.  Virology.. Vol. 217, no. 2. (January): 285-293.
• H. Fu, R. Cai, M. Jia. 1991. The distribution of serotypes and biotypes of Campylobacter jejuni/coli isolated from ten provinces/cities in China.  Chinese J Epidemiol.
• H. Fu. 1987. Campylobacter and Guillain-Barr syndrome.